PCI can be more challenging in high-risk patients presenting with diabetes and ACS. IVUS guidance was associated with improved outcomes among these patients compared to angiography guidance alone. 

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade. 

The Society of Cardiovascular Computed Tomography is cheering as a “huge win” the 2025 CMS payment increase for coronary CTA that more than doubles the current payment and “better aligns with the cost of providing CCTA services." The panel expects the move to bring an increase in CT utilization, more adoption with financial sustainability and greater access in currently underutilized areas.